



(12) Translation of
european patent specification

(11) NO/EP 2552930 B1

NORWAY

(19) NO
(51) Int Cl.
C07H 19/10 (2006.01)
A61K 31/7072 (2006.01)
A61P 31/14 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2016.01.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.08.26
(86)	European Application Nr.	11714465.9
(86)	European Filing Date	2011.03.31
(87)	The European Application's Publication Date	2013.02.06
(30)	Priority	2010.03.31, US, 319513 P 2010.03.31, US, 319548 P 2010.05.20, US, 783680
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Gilead Pharmasset LLC, Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	ROSS, Bruce, S., 155 Del Monte Road, El Granada, CA 94018, USA SOFIA, Michael, Joseph, 3066 Antler Drive, Doylestown, PA 18902, USA PAMULAPATI, Ganapati, Reddy, 1709 Blakesley Drive, San Ramon, CA 94582, USA RACHAKONDA, Suguna, 1272 Sharonbrook Drive, Twinsburg, OH 44087, USA ZHANG, Hai-Ren, 6767 Mason Way, San Jose, CA 95129, USA CHUN, Byoung-Kwon, 135 Heritage Street, Robbinsville, NJ 08691, USA WANG, Peiyuan, 42 Continental Circle, Totowa, NJ 07512, USA
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE
(56)	References Cited:	WO-A1-2010/135569 WO-A2-2008/121634 US-A1- 2007 042 988 MICHAEL J. SOFIA ET AL: "Discovery of a beta-D-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 19, 16 September 2010 (2010-09-16), pages 7202-7218, XP55004442, ISSN: 0022-2623, DOI: 10.1021/jm100863x

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat representert ved formelen S_P-4:



som har XRPD 20-refleksjoner (°) på ca.: 6,1; 8,2; 10,4; 12,7; 17,2; 17,7; 18,0; 18,8; 19,4; 19,8; 20,1; 20,8; 21,8 og 23,3.

2. Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge krav 1, som har XRPD 20-refleksjoner (°) på ca: 6,08; 8,2; 10,38; 10,85; 12,17; 12,7; 13,73; 14,1; 15,91; 16,83; 17,17; 17,66; 17,95; 18,79; 19,1; 19,41; 19,8; 20,11; 20,82; 21,81; 22,03; 23,03; 23,26; 23,64; 23,89 og 24,73 med intensiteter (%) på henholdsvis 66,7; 62,1; 29,8; 10,4; 12,0; 66,4; 14,9; 13,8; 3,1; 8,7; 19,7; 56,2; 37,7; 59,0; 14,3; 37,2; 46,0; 68,8; 100,0; 36,8; 7,4; 14,2; 21,6; 6,3; 7,0 og 3,3.

3. Farmasøytisk preparat omfattende krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge krav 1 eller 2, og et farmasøytisk akseptabelt medium.

4. Farmasøytisk preparat ifølge krav 3, videre omfattende et annet antiviralt middel.

5. Farmasøytisk preparat ifølge krav 4, hvor det annet antivirale midlet er en HCV-NS3-proteaseinhibitor.

6. Farmasøytisk preparat ifølge krav 4, hvor det annet antivirale midlet er en HCV-NS5A-inhibitor.

5 **7.** Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge krav 1 eller 2, for anvendelse som et medikament.

10 **8.** Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge kravene 1 eller 2, for anvendelse ved behandling av en hepatitt C virusinfeksjon.

15 **9.** Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat for anvendelse ifølge krav 8, for anvendelse i kombinasjon med et annet antiviralt middel.

20 **10.** Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat for anvendelse ifølge krav 9, hvor det annet antivirale midlet er en HCV-NS3-proteaseinhibitor.

25 **11.** Krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat for anvendelse ifølge krav 9, hvor det annet antivirale midlet er en HCV-NS5A-inhibitor.

30 **12.** Medikament omfattende krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge kravene 1 eller 2.

13. Medikament ifølge krav 12, videre omfattende et annet antiviralt middel.

35 **14.** Medikament ifølge krav 13, hvor det annet antivirale midlet er en HCV-NS3-proteaseinhibitor.

15. Medikament ifølge i krav 13, hvor det annet antivirale midlet er en HCV-NS5A-inhibitor.

5 **16.** Anvendelse av en krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge kravene 1 eller 2, ved fremstilling av et medikament for behandling av en hepatitt C virusinfeksjon.

10 **17.** Anvendelse av en krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat ifølge krav 1 eller 2, og et annet antivirumiddel for fremstilling av et medikament for behandling av en hepatitt C virusinfeksjon.

15 **18.** Anvendelse ifølge krav 17, hvor det annet antivirale midlet er en HCV-NS3-proteaseinhibitor.

19. Anvendelse ifølge krav 17, hvor det annet antivirale midlet er en HCV-NS5A-inhibitor.